Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Committee Recommends Approval of Dabigatran Etexilate for Stroke Prevention

By Pharmaceutical Processing | September 21, 2010

The FDA Cardiovascular and Renal Drugs Advisory
Committee has voted 9 to 0 in favor of approving dabigatran etexilate
for stroke prevention in patients with atrial fibrillation (AFib).  An
estimated 2.3 million Americans have AFib and the prevalence is
expected to increase 2.5 fold to 5.6 million by 2050, reflecting the
growing population of elderly individuals.

For 50 years, warfarin has been the only oral anticoagulant available
in the U.S. for stroke prevention in patients with AFib. Current
guidelines for patients with non-valvular AFib treated with warfarin
recommend maintaining an INR control range of 2.0-3.0 through regular
blood monitoring and dose adjustments.(2) The RE-LY study established
the safety and efficacy profile of dabigatran(3) without INR monitoring,
dose adjustments or food restrictions.(3)

“We are pleased with the committee’s unanimous recommendation, which
marks an important step in advancing care for patients with atrial
fibrillation,” said Christopher Corsico,
M.D., M.P.H., U.S. medical director, Boehringer Ingelheim
Pharmaceuticals, Inc. “We believe dabigatran etexilate will offer
patients and doctors the first new treatment option for stroke
prevention in atrial fibrillation in more than 50 years. We look forward
to working with the FDA as it finalizes its review of dabigatran.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE